|
GINMU >
03 紀要 >
031 Journal of Nara Medical Association >
Vol.60 No.3-4 >
Please use this identifier to cite or link to this item:
http://hdl.handle.net/10564/1090
|
| Title: | ADJUVANT CHEMOTHERAPY WITH CISPLATIN / CYCLOPHOSPHAMIDE / DOXORUBICIN FOR PATIENTS WITH UROTHELIAL CARCINOMA OF THE UPPER URINARY TRACT |
| Authors: | Chihara, Yosmtomo
Fujimoto, Kiyohide
Miyake, Makito
Anai, Satoshi
Hirayama, Akihide |
| Keywords: | upper urmary tract
urothelial carcinoma
adjuvant chemotherapy |
| Issue Date: | 31-Aug-2009 |
| Publisher: | 奈良医学会 |
| Citation: | Journal of Nara Medical Association Vol.60 No.3-4 p.93-102 |
| Abstract: | Background Urothelial carcinoma of the upper urinary tract is relatively uncommon and
the benefit of adjuvant chemotherapy has not yet been established. We evaluated the
efficacy of adjuvant chemotherapy after radical surgery for patients with primary
urothelial carcinoma of the renal pelvis and ureter in a randomized controlled trial.
Methods Forty patients who underwent radical surgery for localized and locally-invasive
upper urinary tract carcinoma without metastasis were randomly assigned to two groups
treated with and without adjuvant chemotherapy using cisplatin, cyclophosphamide and
doxorubicin (CISCA) to compare the overall, cancer-specific, and recurrence-free survivals
between them. UFT was administered orally at a dose of 200-400 mg/day to both groups
for 2 years after surgery. Results The median follow-up was 80.5 months. The overall
survival and cancer-specific survival rates showed no significant differences (P=0.61 and
P=O.28, respectively) between the two groups. The 10-year recurrence-free survival rates
also showed no difference between the 2 groups treated with and without adjuvant
chemotherapy (68.8% and 54.4%, respectively, P=0.20). All recurrent cases showed
recurrence of non-muscle invasive bladder cancer, and thereafter only one patient
progressed with distant metastasis. The morbidity of recurrence, particularly within 2
years, and the total number of recurrences tended to be smaller in the adjuvant
chemotherapy group than in the non-adjuvant chemotherapy group (P＜0.063). Conclusion
Adjuvant chemotherapy with CISCA after radical surgery showed no significant survival
benefit for the patients with localized and locally-invasive urothelial carcinoma of the
upper urinary tract while recurrence of bladder cancer decreased significantly in the
adjuvant chemotherapy group compared to the non-adjuvant group. |
| URI: | http://hdl.handle.net/10564/1090 |
| ISSN: | 13450069 |
| Appears in Collections: | Vol.60 No.3-4
|
Files in This Item:
| File |
Description |
Size | Format |
|---|
| 093-102p.ADJUVANT CHEMOTHERAPY WITH CISPLATINCYCLOPHOSPHAMIDEDOXORUBICIN.pdf | | 940Kb | Adobe PDF | View/Open |
|
All items in DSpace are protected by copyright, with all rights reserved.
|
